New Pharmaceutical Options for Patients with Allergic and Asthma-Related Diseases: Balancing Effectiveness and Safety in Selection of Specific Therapies.
Jul 2026· Annals of Allergy, Asthma & Immunology· 0 citations
Medicine
TL;DR
The increasing complexity of therapeutic selection, underscores the need for shared decision-making and long term surveillance to ensure successful therapeutic outcomes while prioritizing patient safety.
Abstract
Targeted immunotherapies have expanded treatment options for allergic and immunologic diseases by enabling selective modulation of key inflammatory pathways. However, their growing use necessitates careful evaluation of safety profiles and long-term risks. This review examines the mechanisms of action, safety considerations, and clinical implications of emerging monoclonal antibody and small-molecule therapies used in allergic and immunologic diseases. Monoclonal antibodies targeting IgE, IL-5/IL-5Rα, IL-4Rα, IL-13, TSLP, and IL-31 demonstrate efficacy across a range of atopic conditions, including asthma, atopic dermatitis, and chronic urticaria. They are generally well tolerated, though associated with adverse events such as anaphylaxis, conjunctivitis, eosinophilia, and herpes virus reactivation. Small-molecule therapies, including Janus kinase (JAK), Bruton's tyrosine kinase (BTK), and phosphodiesterase-4 (PDE4) inhibitors, expand treatment options by targeting intracellular signaling pathways and offering broader immunomodulatory effects. Among these, JAK inhibitors carry boxed warnings for major adverse cardiovascular events, thromboembolism, malignancy, and viral reactivation. Second-generation BTK inhibitors and PDE4 inhibitors demonstrate comparatively favorable safety profiles, though tolerability could remain an issue for PDE4 inhibitors. Despite promising short-term safety and efficacy, long-term risks still pose a question given limited longitudinal data. The increasing complexity of therapeutic selection, underscores the need for shared decision-making and long term surveillance to ensure successful therapeutic outcomes while prioritizing patient safety.
Biologics have revolutionized the treatment of severe allergic diseases in children that cannot be controlled by conventional treatments. These diseases are commonly driven by dysregulation of immune response, often driven by Type 2 pathways. By targeting them, biologics have the potential for treating one or more alle...
H. D. den Dekker, Amandine Divaret Chauveau, B. Sterling et al.· Pediatric Allergy and Immuno...· 0 citations
Abstract Severe pediatric asthma is a heterogeneous inflammatory disease that is most commonly driven by type 2 (T2) inflammation. Because respiratory viral infections are the leading triggers of asthma exacerbations in children, this review examines the effects of biologic therapies on infection-related outcomes and a...
Rossella Sica, Francesco Catamerò, Simone Foti Randazzese et al.· ImmunoTargets and Therapy· 0 citations
It is concluded that biologic-enabled AIT is a promising but insufficiently defined strategy, and the prospective trials, standardized phenotyping, and safety registries needed to establish it as an evidence-based clinical pathway are outlined.
B. Jentzsch, A. Hoheisel, K. Gashynova et al.· Frontiers in Allergy· 0 citations
Severe pediatric asthma remains a significant clinical challenge despite advances in conventional therapy. Some children continue to experience persistent symptoms, recurrent exacerbations, and substantial morbidity despite optimized treatment with inhaled corticosteroids and long-acting bronchodilators. Advances in th...
D. Moriki, M. Kalogiannis, M. Tsouprou et al.· Allergies· 1 citation
Severe asthma is a difficult-to-control airway disease with pronounced heterogeneity in both clinical manifestations and underlying inflammatory mechanisms. This review examines the mechanisms, biomarkers, and biologic therapies of severe asthma, with a focus on biomarker-guided treatment selection and emerging precisi...
A deeper understanding of psoriasis immunopathogenesis can transform treatment approaches from broad immunosuppression to precision-targeted therapies, and continued development of cytokine- and signaling pathway-specific agents is expected to improve long-term disease control, safety, and personalized patient outcomes...
Rahul Kadiyan, Molly Maheshwari, S. Latha et al.· Journal of drug targeting (P...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.